1.
Rev. esp. enferm. dig
; 112(11): 889-890, nov. 2020. ilus
Article
in Spanish
| IBECS
| ID: ibc-198782
ABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Adenocarcinoma of Lung/drug therapy , Lung Neoplasms/drug therapy , Antineoplastic Agents, Immunological/adverse effects , Enterocolitis/chemically induced , Enterocolitis/drug therapy , Infliximab/therapeutic use , Gastrointestinal Agents/therapeutic use , Ipilimumab/adverse effects , Nivolumab/adverse effects , Adenocarcinoma of Lung/complications , Lung Neoplasms/complications , Tomography, X-Ray Computed
2.
Rev Esp Enferm Dig
; 112(11): 889-890, 2020 11.
Article
in English
| MEDLINE
| ID: mdl-33054275
ABSTRACT
Immunotherapy is gaining significance in the management of oncological disease. It has demonstrated high levels of efficacy, though it also has hitherto unknown side effects, such as colitis. We present the first case of immune checkpoint inhibitor colitis (nivolumab+ipilimumab) refractory to corticoids treated in our hospital.
